Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SL7207
- Development stage
- Preclinical
- Lead developer
- University of California, Berkeley
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
SL7207 is an attenuated, auxotrophic strain of *Salmonella enterica* serovar Typhimurium, specifically characterized by a mutation in the *aroA* gene. This mutation prevents the synthesis of essential aromatic amino acids, rendering the bacteria dependent on external sources and limiting its virulence in host tissues. SL7207 is extensively studied as a live bacterial vector for cancer immunotherapy and vaccine delivery. In preclinical models, such as melanoma, systemic administration of SL7207 has demonstrated the ability to arrest tumor growth by remodeling the tumor microenvironment. It promotes a pro-inflammatory state by inducing the expression of Th1 cytokines, including interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-12 (IL-12), and by recruiting Ly6C+ MHCII+ inflammatory monocytes to the tumor site.
- Other names
- Salmonella enterica serovar Typhimurium aroA mutantSalmonella typhimurium SL7207aroA-deficient Salmonella typhimurium
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL12 (Interleukin-12)IFNG (Interferon gamma)
Beyond the preview
Go deeper on SL7207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SL7207.